Title : Metastatic castration-resistant prostate cancer: targeting the mechanisms of resistance to abiraterone acetate and enzalutamide.

Pub. Date : 2015

PMID : 26134919






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Although the impressive clinical activity of new hormonal agents, such as the second-generation AR antagonist enzalutamide (formerly MDV3100) and the selective inhibitor of cytochrome P450 17A1 (CYP17A1) abiraterone acetate (AA), in patients with metastatic castration-resistant prostate cancer (mCRPC), innate or acquired resistance invariably arises. Abiraterone Acetate cytochrome P450 family 17 subfamily A member 1 Homo sapiens
2 Although the impressive clinical activity of new hormonal agents, such as the second-generation AR antagonist enzalutamide (formerly MDV3100) and the selective inhibitor of cytochrome P450 17A1 (CYP17A1) abiraterone acetate (AA), in patients with metastatic castration-resistant prostate cancer (mCRPC), innate or acquired resistance invariably arises. Abiraterone Acetate cytochrome P450 family 17 subfamily A member 1 Homo sapiens